Stelios Papadopoulos was probably locked out from purchasing shares during the lead-up to Cometriq's approval. In August, 2010, he bought a load of shares on the open market, when future prospects looked pretty dim for EXEL. As a self-professed long-term investor (5-10 year time frame), you have to think that he might have an interest in buying additional shares in this price range. It'll be interesting to see if he has the confidence to double-down on his conviction that EXEL is still an excellent investment for the long term.
It's also noteworthy that ANDS's Hep C drug had just announced P2 results days before Roche agreed to buy them out at a 265% premium. If you check ANDS's partners they are eerily similar to EXEL's partners. Roche already has a STRONG working relationship with EXEL and they could buy out EXEL for what they have in petty cash ($3B) and not even blink.
Before we all get lined up in full dress whites onboard the USS Lincoln in front of the "MISSION ACCOMPLISHED" banner...s'pose I could requisition a few Warthogs w/ F-16 backup to strafe these frickin shorts back into the Stone Age...??
Might not be much money in it...
But it'd sure make me smile like I'd spent the afternoon in a Quang Tri cathouse.